Biogen agrees to $22M settlement to resolve claims on illegal business

Thursday, 17. December 2020 20:04

United States Justice Department said on Thursday that American pharma company Biogen, Inc. agreed to pay $22 million to resolve claims that it illegally used two foundations as a conduit to pay the copays of Medicare patients taking Biogen’s multiple sclerosis drugs, Avonex and Tysabri.

“Biogen coordinated with ACS to game the foundation system by timing its payments to two foundations with its transfer of financially needy free drug patients, all so that Biogen could obtain significant financial rewards,” said First Assistant United States Attorney Nathaniel R. Mendell.

Under the Anti-Kickback Statute, a pharmaceutical company is prohibited from offering or paying, directly or indirectly, any remuneration, which includes money or any other thing of value, to induce Medicare patients to purchase the company’s drugs.

Related Links: Biogen Inc.
Breaking the News / TF